Clinical Trial

Combined LDR Boost and HDR Whole Gland

Study Description

Combined LDR Boost and HDR Whole Gland

This is a dose finding Phase I/II study of combined focused LDR brachytherapy boost with whole gland single fraction HDR for men with low and intermediate risk prostate cancer and Dominant Intraprostatic Lesion (DIL) visible on multi parametric MRI. Patients will receive 19 Gy HDR to the whole gland with concurrent LDR brachytherapy boost to the DIL, in a sequential dose escalation manner. Primary endpoints are early toxicity.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Radiation - LDR/HDR

Focal LDR to dominant lesion with whole gland 19 Gy HDR

Additional Information

Official Study Title

Dominant Intraprostatic Lesion Boost With Focused LDR Brachytherapy (BT) Integrated to Whole Prostate HDR BT: Safety and Feasibility Analysis

Clinical Trial ID

NCT03323879

ParticipAid ID

7ax3ne